BGMS · Bio Green Med Solution, Inc. · Executive Compensation
$1.00
0.00 (-0.03%)
At close · Oct 22
View the 10-K filed Mar 30, 2026
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of losses, our negative cash flows from operations, our liquidity resources currently on hand, and our dependence on the ability to obtain additional financing to fund our operations after the current resources are exhausted, about which there can be no certainty, have resulted in our assessment that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 14, 2026
Customer concentration
— top 4 customers 55% of revenue
4 customers — 55% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 36% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 7% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 6% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 6% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
Market Cap
$6.62M
Shares
6.62M
Volume · Oct 21
52.98K
Avg daily vol (3M)
76.6K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Spiro Rombotis | President and Chief Executive Officer | $585,000 |
| Paul McBarron | Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary | $333,623 |
| Mark Kirschbaum | MD, Former Senior Vice President and Chief Medical Officer^ | $30,365 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Spiro Rombotis | President and Chief Executive Officer | $661,049 |
| Mark Kirschbaum | MD, Former Senior Vice President and Chief Medical Officer^ | $480,618 |
| Paul McBarron | Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary | $352,615 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Spiro Rombotis | President and Chief Executive Officer | $763,551 |
| Mark Kirschbaum | Former Senior Vice President and Chief Medical Officer | $523,843 |
| Paul McBarron | Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary | $394,675 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Spiro Rombotis | President and Chief Executive Officer | $1,339,226 |
| Mark Kirschbaum | Senior Vice President and Chief Medical Officer | $794,576 |
| Paul McBarron | Executive Vice President, Finance, Chief Financial Officer, Chief Operating Officer, Secretary | $707,860 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Spiro Rombotis | President and Chief Executive Officer 2020 | $1,409,644 |
| Paul McBarron | Executive Vice President, Finance, Chief Operating Officer, Chief Financial Officer, Secretary | $828,712 |
| Mark Kirschbaum | Senior Vice President and Chief Medical Officer | $454,135 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Spiro Rombotis | President and Chief Executive Officer | $1,014,471 |
| Judy Chiao | Vice President, Clinical Development and Regulatory Affairs | $671,121 |
| Paul McBarron | Executive Vice President, Finance, Chief Operating Officer, Chief Financial Officer, Secretary | $542,290 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Spiro Rombotis | President and Chief Executive Officer | $752,824 |
| Judy Chiao | Vice President, Clinical Development and Regulatory Affairs | $529,733 |
| Paul McBarron | Executive Vice President, Finance, Chief Operating Officer, Chief Financial Officer, Secretary | $387,994 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Soon Ping ("Zara") Pappas | independent director | Appointed | 2025-09-25 |
| Kwang Fock Chong | independent director | Resigned | 2025-09-25 |
| Satis Waran Nair Krishnan | independent director | Appointed | 2025-04-02 |
| Inigo Angel Laurduraj | independent director | Appointed | 2025-04-02 |
| Kiu Cu Seng | Secretary | Appointed | 2025-02-27 |
| David Lazar | Secretary | Resigned | 2025-02-27 |
| Chong Kwang Fock | Independent Director | Appointed | 2025-02-27 |
| Spiro Rombotis | non-independent director | Resigned | 2025-02-27 |
| Paul McBarron | non-independent director | Resigned | 2025-02-27 |
| Dr. Samuel L. Barker | independent director | Resigned | 2025-02-27 |
| Kiu Cu Seng | Executive Director and Secretary | Appointed | 2025-02-27 |
| Kiu Cu Seng | Chief Financial Officer | Appointed | 2025-02-27 |
| Datuk Dr. Doris Wong Sing Ee | Director | Appointed | 2025-02-27 |
| Datuk Dr. Doris Wong Sing Ee | Chief Executive Officer | Appointed | 2025-02-27 |
| David Lazar | interim Chief Executive Officer and Secretary | Resigned | 2025-02-27 |
| Karin Walker | Board | Resigned | 2025-01-06 |
| Dr. Robert Spiegel | Board | Resigned | 2025-01-06 |
| Dr. Brian Schwartz | Board | Resigned | 2025-01-06 |
| David Natan | Board | Appointed | 2025-01-06 |
| Dr. Christopher Henney | Board | Resigned | 2025-01-06 |
| Dr. Kenneth Ferguson | Board | Resigned | 2025-01-06 |
| David Lazar | Chief Executive Officer | Appointed | 2025-01-06 |
| David Lazar | Chairman of the Board of Directors | Appointed | 2025-01-06 |
| Kenneth Ferguson | director | Resigned | 2025-01-06 |
| Christopher Henney | director | Resigned | 2025-01-06 |
Leadership
- Datuk Dr. Doris Wong CEO, Board Member
- Datuk Dr. Doris Wong Sing Ee CEO, Board Member
- David E. Lazar CEO
- David Lazar CEO, Chairman
- Dr. Robert Spiegel Chairman
- Dr. Samuel L. Barker Chairman
- Kiu Cu Seng CFO, Board Member
- Avraham Ben-Tzvi Board Member
- Brian Schwartz, M.D. Board Member
- Chong Kwang Fock Board Member
- David Natan Board Member
- Dr. Satis Waran Nair Krishnan Board Member
- Inigo Angel Laurduraj Board Member
- Satis Waran Nair Krishnan Board Member
- Soon Ping ("Zara") Pappas Board Member
- Soon Ping Pappas Board Member